Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Ondine Biomedical, Inc. ( (GB:OBI) ) is now available.
Ondine Biomedical Inc. announced that British Columbia’s Interior Health Authority has adopted Steriwave® nasal decolonization therapy as the standard of care for all total hip and knee replacement surgeries, marking it as the second provincial health authority in Canada to do so. This expansion signifies a significant step in infection prevention, aligning with BC’s healthcare goals and demonstrating substantial cost savings and infection rate reductions, which could enhance Ondine’s market positioning and stakeholder value.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those from multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology and has received various international approvals for its nasal photodisinfection system, Steriwave®.
Average Trading Volume: 162,601
Technical Sentiment Signal: Buy
Current Market Cap: £64.27M
For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.